Skip to main content
APhA DrugInfoLine
Sign in to your APhA membership account
Download a PDF of this month's content | Download a PDF of last month's content |Advanced Search
  • HOME
  • NEURO/PSYCH
    • Neurology
    • Psychiatry
  • HEART/LUNGS
    • Cardiology
    • Focus on Lipids Care
    • Focus on Anticoagulation Care
    • Respiratory
    • Focus on Asthma Care
  • GI/KIDNEYS
    • Gastroenterology
    • Nephrology
  • ENDOCRINE/RHEUM
    • Endocrinology
    • Focus on Diabetes Care
    • Rheumatology
  • ID/CANCERS
    • Infectious Diseases
    • Focus on HIV Care
    • Focus on Immunizations
    • Oncology
  • SELF-CARE
    • Alternative Medicines Corner
    • OTC Medicines Corner
  • PERSONALIZED CARE
    • Drug Interactions Corner
    • Pharmacogenomics Corner
  • Neuro/Psych
    Psychiatry...
    December 18, 2018

    Antipsychotics not useful for ICU delirium

    READ
  • Endocrine/Rheum
    Rheumatology...
    December 18, 2018

    Steroid injection an ideal option for first-time carpal tunnel syndrome

    READ
  • Neuro/Psych
    Psychiatry...
    December 11, 2018

    Quetiapine prescribing decreased after clinicians received...

    READ
  • Heart/Lungs
    Focus on Anticoagulat...
    December 11, 2018

    Aspirin may be good for knee replacement thromboembolism...

    READ
  • Heart/Lungs
    Focus on Asthma Care...
    December 3, 2018

    SMART therapy associated with a lower risk of asthma...

    READ
  • Neuro/Psych
    Neurology...
    December 3, 2018

    Switching antiepileptic suppliers associated with increased...

    READ
  • Neuro/Psych
    Psychiatry...
    November 27, 2018

    Medications used for substance abuse disorders may reduce...

    READ
  • Self-care
    OTC Medicines Corner...
    November 27, 2018

    Factors that may predict sustained efficacy after a short course...

    READ
  • Heart/Lungs
    Focus on Lipids Care...
    November 20, 2018

    Reassessing use of statins for primary prevention in older adults

    READ
  • Neuro/Psych
    Neurology...
    November 20, 2018

    Pharmacists need a better understanding of generic drug approvals

    READ
  • ID/Cancers
    Focus on Immunizations...
    November 13, 2018

    Adolescent vaccinations not associated with fertility problems

    READ
  • Read more about Combined with standard immunosuppressive therapy, drug targets treatment-resistant SAA
  • Read more about New oncology drug targets specific genetic biomarker instead of tumor type
  • Read more about Medications used for substance abuse disorders may reduce suicidality, crime
  • Read more about Factors that may predict sustained efficacy after a short course of OTC PPIs
  • Read more about Product recalled because stoppers for vials contain natural rubber latex
  • Read more about Mylan recalls valsartan products found to contain NDEA
  • Read more about Severe worsening of MS symptoms may occur after stopping fingolimod
  • Read more about FDA warns health professionals, patients not to use Pharm D Solutions' sterile drug products
  • Read more about FDA approves first treatment for patients with rare and life-threatening immune disease
  • Read more about FDA approves new treatment for acute myeloid leukemia

Medication Monitor

NEW DRUG APPROVALS

  • December 11, 2018
    Fish oil triglycerides injectable emulsion
    (Omegaven):
    I.V. lipid emulsion approved for pediatric patients with parenteral nutrition-associated cholestasis
  • November 30, 2018
    Amifampridine
    (Firdapse):
    FDA approves first treatment for Lambert-Eaton myasthenic syndrome
See more New Drug Approvals

SUPPLEMENTAL APPROVALS

  • December 14, 2018
    SUBA-itraconazole
    (Tolsura):
    FDA approves new formulation of itraconazole for certain systemic fungal infections
  • November 30, 2018
    Brentuximab vedotin
    (Adcetris):
    FDA approves expanded use for first-line treatment of peripheral T-cell lymphoma
See more Supplemental Approvals

ALERTS AND RECALLS

  • November 30, 2018
    Genetic tests
    (No trade names):
    FDA warns about genetic tests with unapproved medication response claims
See more Alerts and Recalls

PRODUCT WITHDRAWALS

  • March 26, 2018
    Daclizumab
    (Zinbryta):
    Daclizumab withdrawn after reports of serious inflammatory brain disorders
See more Product withdrawals


                                

Editor's Picks

  • Antipsychotics not useful for ICU delirium
  • Steroid injection an ideal option for first-time...
  • Quetiapine prescribing decreased after clinicians...
  • Aspirin may be good for knee replacement...
  • SMART therapy associated with a lower risk of...

Popular Articles

  • Common antibiotics do not appear to interact with...
  • New oral option for cancer-associated VTE
  • Updated Clostridium difficile guidelines released
  • Pharmacist interventions at black barbershops...
  • New analysis compares efficacy and safety of...

Popular Sections

  • Alerts and Recalls
  • Supplemental Approvals
  • New Drug Approvals
  • Cardiology
  • Alternative Medicines Corner

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

More info

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.

  • Contact Us
  • Section Advisors
  • Terms of Use
  • Privacy Policy